Project Grant R21CA289090
Award Date
2/1/25
Completion Date
1/31/27
Dollars Obligated
$221K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting research to understand the fundamental biological mechanisms underlying ovarian cancer metastasis. The primary awardee, Trustees of Indiana University (doing business as Indiana University Indianapolis), will receive $506,309 over the project period from May 2025 to April 2030 to investigate how microenvironmental signals activate the transcription factor c-Jun and impact chromatin...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $612,288 to the University of Wisconsin-Madison to conduct research on the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche. The goal is to improve understanding of the fundamental biological mechanisms underlying high-grade serous ovarian cancer (HGSOC), which has a 5-year survival rate of just 31%. The award, effective from December 11, 2024 to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore to conduct research on the mechanisms by which chemotherapy used to treat epithelial ovarian cancer (including the high-grade serous ovarian cancer subtype) can paradoxically promote metastasis. The goal is to determine how chemotherapy activates tumor-associated membrane-anchored serine proteases that enable cancer cell...
This Project Grant award, valued at $1,274,742 and funded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to engineer a high-performing microfluidic system for the rapid, non-invasive isolation and expansion of circulating tumor-reactive lymphocytes (CTRLs) from the blood of ovarian cancer patients. The research, conducted by Northwestern University, seeks to develop a first-in-class microfluidic cell sorting and culturing system...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,373,308 to the University of Pittsburgh to conduct research on the role of acetylcarnitine metabolism in ovarian cancer chemoresistance. The project aims to: 1) quantitatively and mechanistically map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, and 2) investigate whether interventions that...
This $392,187 Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program supports research at the University of California, San Diego (UCSD) to investigate how changes in the mechanical properties of the tumor microenvironment contribute to the invasive and metastatic behavior of oral squamous cell carcinoma (OSCC). The project aims to elucidate the mechanisms by which tumor stiffness induces the acquisition and consolidation of "mechanical...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $800,888 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to evaluate a combination therapy approach for treating platinum resistant ovarian cancer. The project aims to assess the safety and tolerability of combining the CLK/DYRK inhibitor Cirtuvivint with the PARP inhibitor Olaparib in patients with BRCA/HRD deficiencies. The research...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...